1
|
Zhang Y, Wang J. Targeting uptake transporters for cancer imaging and treatment. Acta Pharm Sin B 2020; 10:79-90. [PMID: 31993308 DOI: 10.1016/j.apsb.2019.12.005] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2019] [Revised: 09/27/2019] [Accepted: 11/17/2019] [Indexed: 12/11/2022] Open
Abstract
Cancer cells reprogram their gene expression to promote growth, survival, proliferation, and invasiveness. The unique expression of certain uptake transporters in cancers and their innate function to concentrate small molecular substrates in cells make them ideal targets for selective delivering imaging and therapeutic agents into cancer cells. In this review, we focus on several solute carrier (SLC) transporters known to be involved in transporting clinically used radiopharmaceutical agents into cancer cells, including the sodium/iodine symporter (NIS), norepinephrine transporter (NET), glucose transporter 1 (GLUT1), and monocarboxylate transporters (MCTs). The molecular and functional characteristics of these transporters are reviewed with special emphasis on their specific expressions in cancers and interaction with imaging or theranostic agents [e.g., I-123, I-131, 123I-iobenguane (mIBG), 18F-fluorodeoxyglucose (18F-FDG) and 13C pyruvate]. Current clinical applications and research areas of these transporters in cancer diagnosis and treatment are discussed. Finally, we offer our views on emerging opportunities and challenges in targeting transporters for cancer imaging and treatment. By analyzing the few clinically successful examples, we hope much interest can be garnered in cancer research towards uptake transporters and their potential applications in cancer diagnosis and treatment.
Collapse
Key Words
- CT, computed tomography
- Cancer imaging
- DDI, drug–drug interaction
- DTC, differentiated thyroid cancer
- FDA, U.S. Food and Drug Administrations
- FDG, fluorodeoxyglucose
- GLUT, glucose transporter
- IAEA, the International Atomic Energy Agency
- LACC, locally advanced cervical cancer
- LAT, large amino acid transporter
- MCT, monocarboxylate transporter
- MRI, magnetic resonance imaging
- NE, norepinephrine
- NET, norepinephrine transporter
- NIS, sodium/iodine symporter
- Neuroblastoma
- OCT, organic cation transporter
- PET, positron emission tomography
- PHEO, pheochromocytoma
- RA, retinoic acid
- RET, rearranged during transfection
- SLC, solute carrier
- SPECT, single-photon emission computed tomography
- SUV, standardized uptake value
- TFB, tetrafluoroborate
- TSH, thyroid stimulating hormones
- Thyroid cancer
- Uptake transporter
- Warburg effect
- mIBG
- mIBG, iobenguane/meta-iodobenzylguanidine
- vHL, von Hippel-Lindau
Collapse
|
2
|
Aubert G, Barefield DY, Demonbreun AR, Ramratnam M, Fallon KS, Warner JL, Rossi AE, Hadhazy M, Makielski JC, McNally EM. Deletion of Sulfonylurea Receptor 2 in the Adult Myocardium Enhances Cardiac Glucose Uptake and Is Cardioprotective. JACC Basic Transl Sci 2019; 4:251-268. [PMID: 31061927 PMCID: PMC6488756 DOI: 10.1016/j.jacbts.2018.11.012] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2018] [Revised: 11/24/2018] [Accepted: 11/26/2018] [Indexed: 11/05/2022]
Abstract
In the heart, SUR2 couples with a potassium channel to form an adenosine triphosphate–sensitive complex that responds to the energy state of the cell. The authors deleted SUR2 in adult cardiomyocytes and found a shift of the heart toward glycolytic metabolism, which is protective under cardiac stress. SUR2 was found to complex with glucose transporter type 4, the major glucose transporter. Drugs that antagonize the SUR2 receptor may be cardioprotective and useful for managing heart failure.
The adult myocardium relies on oxidative metabolism. In ischemic myocardium, such as the embryonic heart, glycolysis contributes more prominently as a fuel source. The sulfonylurea receptor 2 (SUR2) was previously implicated in the normal myocardial transition from glycolytic to oxidative metabolism that occurs during adaptation to postnatal life. This receptor was now selectively deleted in adult mouse myocardium resulting in protection from ischemia reperfusion injury. SUR2-deleted cardiomyocytes had enhanced glucose uptake, and SUR2 forms a complex with the major glucose transporter. These data identify the SUR2 receptor as a target to shift cardiac metabolism to protect against myocardial injury.
Collapse
Key Words
- 2DG, 2-deoxy-D-glucose
- ABCC9
- EDTA, ethylenediaminetetraacetic acid
- FL Ex5, LoxP sites flanking exon 5
- GFP, green fluorescent protein
- GLUT, glucose transporter
- HEK293T, human embryonic kidney 293T
- KATP, adenosine triphosphate–sensitive potassium
- Kir, inward rectifying potassium channel
- LVDP, left ventricular developed pressure
- MCM, αMHC-MerCreMer
- PCR, polymerase chain reaction
- SUR, sulfonylurea receptor
- ischemia
- potassium ATP channels
- sulfonylurea
Collapse
Affiliation(s)
- Gregory Aubert
- Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago Illinois
| | - David Y Barefield
- Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago Illinois
| | - Alexis R Demonbreun
- Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago Illinois
| | - Mohun Ramratnam
- Division of Cardiology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin
| | - Katherine S Fallon
- Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago Illinois
| | - James L Warner
- Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago Illinois
| | - Ann E Rossi
- Section of Cardiology, University of Chicago, Chicago Illinois
| | - Michele Hadhazy
- Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago Illinois
| | - Jonathan C Makielski
- Division of Cardiology, Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin
| | | |
Collapse
|
3
|
Pinweha P, Rattanapornsompong K, Charoensawan V, Jitrapakdee S. MicroRNAs and oncogenic transcriptional regulatory networks controlling metabolic reprogramming in cancers. Comput Struct Biotechnol J 2016; 14:223-33. [PMID: 27358718 PMCID: PMC4915959 DOI: 10.1016/j.csbj.2016.05.005] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Revised: 05/25/2016] [Accepted: 05/27/2016] [Indexed: 12/15/2022] Open
Abstract
Altered cellular metabolism is a fundamental adaptation of cancer during rapid proliferation as a result of growth factor overstimulation. We review different pathways involving metabolic alterations in cancers including aerobic glycolysis, pentose phosphate pathway, de novo fatty acid synthesis, and serine and glycine metabolism. Although oncoproteins, c-MYC, HIF1α and p53 are the major drivers of this metabolic reprogramming, post-transcriptional regulation by microRNAs (miR) also plays an important role in finely adjusting the requirement of the key metabolic enzymes underlying this metabolic reprogramming. We also combine the literature data on the miRNAs that potentially regulate 40 metabolic enzymes responsible for metabolic reprogramming in cancers, with additional miRs from computational prediction. Our analyses show that: (1) a metabolic enzyme is frequently regulated by multiple miRs, (2) confidence scores from prediction algorithms might be useful to help narrow down functional miR-mRNA interaction, which might be worth further experimental validation. By combining known and predicted interactions of oncogenic transcription factors (TFs) (c-MYC, HIF1α and p53), sterol regulatory element binding protein 1 (SREBP1), 40 metabolic enzymes, and regulatory miRs we have established one of the first reference maps for miRs and oncogenic TFs that regulate metabolic reprogramming in cancers. The combined network shows that glycolytic enzymes are linked to miRs via p53, c-MYC, HIF1α, whereas the genes in serine, glycine and one carbon metabolism are regulated via the c-MYC, as well as other regulatory organization that cannot be observed by investigating individual miRs, TFs, and target genes.
Collapse
Key Words
- 2-HG, 2-hydroxyglutarate
- ACC, acetyl-CoA carboxylase
- ACL, ATP-citrate lyase
- BRCA1, breast cancer type 1 susceptibility protein
- Cancer
- FAS, fatty acid synthase
- FH, fumarate hydratase
- G6PD, glucose-6-phosphate dehydrogenase
- GDH, glutamate dehydrogenase
- GLS, glutaminase
- GLUT, glucose transporter
- HIF1α, hypoxia inducible factor 1α
- HK, hexokinase
- IDH, isocitrate dehydrogenase
- MCT, monocarboxylic acid transporter
- ME, malic enzyme
- Metabolism
- MicroRNA
- Oncogene
- PC, pyruvate carboxylase
- PDH, pyruvate dehydrogenase
- PDK, pyruvate dehydrogenase kinase
- PEP, phosphoenolpyruvate
- PEPCK, phosphoenolpyruvate carboxykinase
- PFK, phosphofructokinase
- PGK, phosphoglycerate kinase (PGK)
- PHGDH, phosphoglycerate dehydrogenase
- PKM, muscle-pyruvate kinase
- PPP, pentose phosphate pathway
- PSAT, phosphoserine aminotransferase
- PSPH, phosphoserine phosphatase
- SDH, succinate dehydrogenase
- SHMT, serine hydroxymethyl transferase
- SREBP1, sterol regulatory element binding protein 1
- TCA, tricarboxylic acid
- TFs, transcription factors
- Transcriptional regulation network
- c-MYC, V-myc avian myelocytomatosis viral oncogene homolog
- miR/miRNA, LDH, lactate dehydrogenase micro RNA
- p53, tumor protein p53
Collapse
Affiliation(s)
- Pannapa Pinweha
- Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
| | | | - Varodom Charoensawan
- Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
- Integrative Computational BioScience (ICBS) Center, Mahidol University, Nakhon Pathom 73170, Thailand
| | - Sarawut Jitrapakdee
- Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
| |
Collapse
|
4
|
Abstract
Background Like all healthy ecosystems, richness of microbiota species characterizes the GI microbiome in healthy individuals. Conversely, a loss in species diversity is a common finding in several disease states. This biome is flooded with energy in the form of undigested and partially digested foods, and in some cases drugs and dietary supplements. Each microbiotic species in the biome transforms that energy into new molecules, which may signal messages to physiological systems of the host. Scope of review Dietary choices select substrates for species, providing a competitive advantage over other GI microbiota. The more diverse the diet, the more diverse the microbiome and the more adaptable it will be to perturbations. Unfortunately, dietary diversity has been lost during the past 50 years and dietary choices that exclude food products from animals or plants will narrow the GI microbiome further. Major conclusion Additional research into expanding gut microbial richness by dietary diversity is likely to expand concepts in healthy nutrition, stimulate discovery of new diagnostics, and open up novel therapeutic possibilities.
Collapse
Key Words
- Agrobiodiversity
- Dietary diversity
- FDA, Food and Drug Administration
- FODMAP, fermentable oligo-, di-, monosaccharides and polyols
- FXR, farnesoid X receptor
- GI, gastrointestinal
- GIMM, GI microbiome modulator
- GLP-I, glucagon-like peptide-1
- GLUT, glucose transporter
- Gastrointestinal
- HMP, Human Microbiome Project
- MCFA, medium chain fatty acids
- MetaHIT, Metagenomics project of the Human Intestinal Tract
- Microbiome
- Microbiota
- Microbiota richness
- NIH, National Institutes of Health
- PYY, peptide YY
- RYGB, Roux-en-Y gastric bypass
- SCFA, short chain fatty acid
- SGLTs, sodium–glucose cotransporter
- TMA, trimethylamine
- TMAO, trimethylamine-N-oxide
- VSG, vertical sleeve gastrectomy
Collapse
Affiliation(s)
- Mark L Heiman
- MicroBiome Therapeutics, 1316 Jefferson Avenue, New Orleans, LA 70115, USA.
| | - Frank L Greenway
- Pennington Biomedical Research Center, Louisiana State University System, 6400 Perkins Road, Baton Rouge, LA 70808, USA
| |
Collapse
|
5
|
Heimann E, Nyman M, Degerman E. Propionic acid and butyric acid inhibit lipolysis and de novo lipogenesis and increase insulin-stimulated glucose uptake in primary rat adipocytes. Adipocyte 2015; 4:81-8. [PMID: 26167409 PMCID: PMC4496978 DOI: 10.4161/21623945.2014.960694] [Citation(s) in RCA: 64] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/08/2014] [Revised: 07/10/2014] [Accepted: 08/28/2014] [Indexed: 01/21/2023] Open
Abstract
Fermentation of dietary fibers by colonic microbiota generates short-chain fatty acids (SCFAs), e.g., propionic acid and butyric acid, which have been described to have “anti-obesity properties” by ameliorating fasting glycaemia, body weight and insulin tolerance in animal models. In the present study, we therefore investigate if propionic acid and butyric acid have effects on lipolysis, de novo lipogenesis and glucose uptake in primary rat adipocytes. We show that both propionic acid and butyric acid inhibit isoproterenol- and adenosine deaminase-stimulated lipolysis as well as isoproterenol-stimulated lipolysis in the presence of a phosphodiesterase (PDE3) inhibitor. In addition, we show that propionic acid and butyric acid inhibit basal and insulin-stimulated de novo lipogenesis, which is associated with increased phosphorylation and thus inhibition of acetyl CoA carboxylase, a rate-limiting enzyme in fatty acid synthesis. Furthermore, we show that propionic acid and butyric acid increase insulin-stimulated glucose uptake. To conclude, our study shows that SCFAs have effects on fat storage and mobilization as well as glucose uptake in rat primary adipocytes. Thus, the SCFAs might contribute to healthier adipocytes and subsequently also to improved energy metabolism with for example less circulating free fatty acids, which is beneficial in the context of obesity and type 2 diabetes.
Collapse
Key Words
- ACC, acetyl-CoA carboxylase
- ADA, adenosine deaminase
- AMPK, AMP-activated protein kinase
- BA, butyric acid
- BSA, bovine serum albumin
- FFAR, free fatty acid receptor
- GLUT, glucose transporter
- GPCR, G-protein-coupled receptor
- HSL, hormone-sensitive lipase
- ISO, isoproterenol
- KRBH, Krebs-Ringer bicarbonate-HEPES
- KRH, Krebs Ringer-HEPES
- PA, propionic acid
- PDE, cyclic nucleotide phosphodiesterase
- SCFAs, short-chain fatty acids
- T2D, type 2 diabetes
- adipocyte
- metabolism
- obesity
- short-chain fatty acid
- type 2 diabetes
Collapse
|
6
|
Abstract
Mathematical modeling of the electrical activity of the pancreatic β-cell has been extremely important for understanding the cellular mechanisms involved in glucose-stimulated insulin secretion. Several models have been proposed over the last 30 y, growing in complexity as experimental evidence of the cellular mechanisms involved has become available. Almost all the models have been developed based on experimental data from rodents. However, given the many important differences between species, models of human β-cells have recently been developed. This review summarizes how modeling of β-cells has evolved, highlighting the proposed physiological mechanisms underlying β-cell electrical activity.
Collapse
Key Words
- ADP, adenosine diphosphate
- ATP, adenosine triphosphate
- CK, Chay-Keizer
- CRAC, calcium release-activated current
- Ca2+, calcium ions
- DOM, dual oscillator model
- ER, endoplasmic reticulum
- F6P, fructose-6-phosphate
- FBP, fructose-1,6-bisphosphate
- GLUT, glucose transporter
- GSIS, glucose-stimulated insulin secretion
- HERG, human eter à-go-go related gene
- IP3R, inositol-1,4,5-trisphosphate receptors
- KATP, ATP-sensitive K+ channels
- KCa, Ca2+-dependent K+ channels
- Kv, voltage-dependent K+ channels
- MCU, mitochondrial Ca2+ uniporter
- NCX, Na+/Ca2+ exchanger
- PFK, phosphofructokinase
- PMCA, plasma membrane Ca2+-ATPase
- ROS, reactive oxygen species
- RyR, ryanodine receptors
- SERCA, sarco-endoplasmic reticulum Ca2+-ATPase
- T2D, Type 2 Diabetes
- TCA, trycarboxylic acid cycle
- TRP, transient receptor potential
- VDCC, voltage-dependent Ca2+ channels
- Vm, membrane potential
- [ATP]i, cytosolic ATP
- [Ca2+]i, intracellular calcium concentration
- [Ca2+]m, mitochondrial calcium
- [Na+], Na+ concentration
- action potentials
- bursting
- cAMP, cyclic AMP
- calcium
- electrical activity
- ion channels
- mNCX, mitochondrial Na+/Ca2+ exchanger
- mathematical model
- β-cell
Collapse
Affiliation(s)
- Gerardo J Félix-Martínez
- Department of Electrical Engineering; Universidad
Autónoma Metropolitana-Iztapalapa; México, DF,
México
- Correspondence to: Gerardo J
Félix-Martínez;
| | | |
Collapse
|